UBS Group
PGEN icon

UBS Group’s Precigen PGEN Stock Holding History

UBS Group’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-154,600
Closed -$1.58M – 9349
2020
Q4 		$1.58M Hold
154,600
– – ﹤0.01% 3619
2020
Q3 		$541K Buy
+154,600
New +$734K ﹤0.01% 4122
2015
Q2 		– Sell
-105
Closed -$5K – 8751
2015
Q1 		$5K Sell
105
-3,976
-97% -$143K ﹤0.01% 8116
2014
Q4 		$107K Buy
+4,081
New +$89.5K ﹤0.01% 5640

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

UBS Group's PGEN Position: Q1 2026 in Review

UBS Group reduced its Precigen (PGEN) stake by 23% in Q1 2026, selling an estimated $843K and leaving 686,084 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #4709.

UBS Group first reported a position in PGEN in Q4 2014 and has held it in 46 quarters since. The position peaked at $8.07M in Q4 2015. 205 funds tracked by Wall St. Rank hold PGEN as of Q1 2026.

  • UBS Group held 686,084 shares of Precigen worth $2.66M as of Q1 2026.
  • UBS Group sold 205,344 Precigen shares in Q1 2026, an estimated $843K.
  • Precigen made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4709 holding.
  • UBS Group first reported a position in Precigen in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Precigen position peaked at $8.07M in Q4 2015.
  • 205 funds tracked by Wall St. Rank held Precigen as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.